Site-specific protein-polymer conjugate micelles with dramatically enhanced pharmacology
Hua Lu
Protein drugs are increasingly used in the clinical treatment of various diseases including cancer and infectious diseases because of their specificity and high biological activity [1] . Nevertheless, the efficacy of protein drugs is constrained by their relatively short in vivo circulation half-life [2] . As a result, frequent administration at high concentrations is often required, leading to undesirable side effects and poor patient compliance [3] .
Conjugating hydrophilic and stealth polymers to proteins has long been proven effective for improving the in vivo properties including circulation half-life, biodistribution, and even final therapeutic efficacy [4] . In the past decades, many synthetic polymers like poly(ethylene glycol) (PEG), poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA), poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC) and biopolymers like polypeptides and polysaccharides have been employed for the purpose [5] . For instance, two PEGylated recombinant human interferon alpha (IFN-α), PEG-Intron from Schering-Plough and PEGASYS from Roche [6, 7] , are FDA-approved long-acting IFN-α. PEG-Intron is composed of IFN-α2b and a linear PEG of 12 kDa, while PEGASYS consists of IFN-α2a and a branched PEG of 40 kDa. However, both products are non-specifically labeled. As a result, the non-specific PEGylation leads to a heterogeneous product mixture with dramatically reduced bioactivity. For example, PEGASYS was inclusive of at least 9 positional isomers with significantly different bioactivities, respectively [8] . Hence, site-specific conjugation between protein and polymer represents an emerging direction in the development of long-acting protein drugs. On the other hand, the polymer conjugation onto protein usually leads to the decrease of bioactivity largely due to the physical shielding effect. Furthermore, this effect would grow with the increase in the chain length of conjugated polymer, even though a longer conjugated polymer usually means a better in vivo pharmacokinetics behavior [9] . Thus, it falls into a dilemma of how to balance the bioactivity and in vivo pharmacokinetics.
In a recent publication of Journal of the American Chemical Society [10] , Prof. Weiping Gao from Tsinghua University, put forward such a novel strategy called "Sitespecific in situ polymerization induced self-assembly, SI-PISA", to simultaneously solve the site-specific conjugation issue and the contradiction between bioactivity and in vivo pharmacokinetics. For the first time, they combined the polymerization induced self-assembly (PISA) and sitespecific in situ growth (SIG) to grow an amphiphilic block copolymer (POEGMA-PHPMA) directly from the C-terminus of IFN-α, forming IFN-POEGMA-PHPMA conjugate micelles in situ via the supramolecular selfassembly mechanism (Fig. 1) . The self-assembled proteinpolymer conjugate micelles possessed a uniform size around 100 nm, which was confirmed by several methods including dynamic light scattering (DLS), atom force microscopy (AFM) and cryo-transmission electron microscopy (Cryo-TEM). It is noteworthy that the in vitro bioactivity of the micelles was 21.5-fold higher than that of PEGASYS. Moreover, the micelles also exhibited a longer in vivo half-life of 83.8 h, which was 100-and 1.7-fold longer than those of IFN-α (0.8 h) and PEGASYS (49.5 h), respectively. The combination of high bioactivity and long circulation half-life endued almost completely inhibition effect on the growth of subcutaneous xenografts of human ovarian tumor in nude mice without obvious systemic toxicity, while PEGASYS and IFN-α had much weaker inhibition effect toward tumor growth. These encouraging results may provide a promising possibility for the final treatment of cancer and viral diseases.
Therefore, these findings indicate that SI-PISA strategy may open up new opportunities for the development of next-generation long-acting protein drugs. This work may also inspire more advanced chemistry technologies addressing unmet medical need in clinic.
